Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey

Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated chil...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of infectious diseases 2012-05, Vol.16 (5), p.e354-e357
Hauptverfasser: Yüksel, Nurullah, Beyazova, Ufuk, Balci, Işil Fidan, Aksakal, Fatma Nur, Çamurdan, Aysu Duyan, Sahin, Figen, Rota, Seyyal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e357
container_issue 5
container_start_page e354
container_title International journal of infectious diseases
container_volume 16
creator Yüksel, Nurullah
Beyazova, Ufuk
Balci, Işil Fidan
Aksakal, Fatma Nur
Çamurdan, Aysu Duyan
Sahin, Figen
Rota, Seyyal
description Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in infants vaccinated with these different schedules. Methods Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and Hib for the first one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series. Results Anti-polyribosylribitol phosphate (anti-PRP) titers ≥0.15 μg/ml were similar in groups 1, 2, and 3. However, in group 1, who received all the vaccines at separate sites, ≥ l.0 μg/ml long-lasting antibody titers and anti-PRP geometric mean titers were higher ( p = 0.001). Conclusion This study showed that even one dose administered in combination with other vaccines in a primary series decreased the level of anti-PRP.
doi_str_mv 10.1016/j.ijid.2012.01.005
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1001953768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1201971212000380</els_id><sourcerecordid>1001953768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-2d05eb30c22fafdd265d818420d8bd9ddcc92cc3813d47877f65caf9849b96c63</originalsourceid><addsrcrecordid>eNp9UktuFDEQbSEQCYELsEBespnBdv_cEkJCUSCRIrEgrC23XZ1x020P_kw0WXEHjsUtOAnVzIQFC1Zl6X1cVa-K4iWja0ZZ82Zc29GaNaeMrylbU1o_Kk6ZaMWqrBl7jG-EVl3L-EnxLMaRUlo1jXhanHBeipZV1Wnx82qes_O34Ky2aU_8QBS5VDD77cZOORLrhimDu1dA0n4LpP_1_UeCpBxi2rsx36oEZKe0tg7I3QYcUWa2zsYEAQyJsFUBKRN6B3RD0dwj1TxoIhkQ2AY7q7AndmnH3qtkvVvY6c4v30TQOdkdEPcHUROJegMmT7B0SG5y-Ar758WTQU0RXhzrWfHlw8XN-eXq-tPHq_P31ytd1XVacUNr6EuqOR_UYAxvaiOYqDg1ojedMVp3XOtSsNJUrWjboam1GjpRdX3X6KY8K14ffLfBf8sQk5xt1DBNyoHPUTJKWVeXbSOQyg9UHXyMAQZ5HBRJcglRjnIJUS4hSsokhoiiV0f_3M9g_koeUkPC2wMBcMqdhSCjtuA0GBtAJ2m8_b__u3_kesLAtJpwiRBHnwNuGOeQETXy83JGyxVhpbQUtPwNcwLKbg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1001953768</pqid></control><display><type>article</type><title>Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Yüksel, Nurullah ; Beyazova, Ufuk ; Balci, Işil Fidan ; Aksakal, Fatma Nur ; Çamurdan, Aysu Duyan ; Sahin, Figen ; Rota, Seyyal</creator><creatorcontrib>Yüksel, Nurullah ; Beyazova, Ufuk ; Balci, Işil Fidan ; Aksakal, Fatma Nur ; Çamurdan, Aysu Duyan ; Sahin, Figen ; Rota, Seyyal</creatorcontrib><description>Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in infants vaccinated with these different schedules. Methods Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and Hib for the first one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series. Results Anti-polyribosylribitol phosphate (anti-PRP) titers ≥0.15 μg/ml were similar in groups 1, 2, and 3. However, in group 1, who received all the vaccines at separate sites, ≥ l.0 μg/ml long-lasting antibody titers and anti-PRP geometric mean titers were higher ( p = 0.001). Conclusion This study showed that even one dose administered in combination with other vaccines in a primary series decreased the level of anti-PRP.</description><identifier>ISSN: 1201-9712</identifier><identifier>EISSN: 1878-3511</identifier><identifier>DOI: 10.1016/j.ijid.2012.01.005</identifier><identifier>PMID: 22387144</identifier><language>eng</language><publisher>Canada: Elsevier Ltd</publisher><subject><![CDATA[Anti-PRP antibodies ; Antibodies, Bacterial - blood ; Diphtheria Toxoid - administration & dosage ; Haemophilus Infections - prevention & control ; Haemophilus influenzae type b ; Haemophilus influenzae type b - immunology ; Haemophilus Vaccines - administration & dosage ; Haemophilus Vaccines - immunology ; Humans ; Immunogenicity ; Infant ; Infectious Disease ; Mass Vaccination ; Pertussis Vaccine - administration & dosage ; Poliovirus Vaccine, Inactivated - administration & dosage ; Polysaccharides - immunology ; Population Surveillance ; Pulmonary/Respiratory ; Tetanus Toxoid - administration & dosage ; Turkey ; Vaccination schedule ; Vaccines, Acellular - administration & dosage ; Vaccines, Combined - administration & dosage ; Vaccines, Combined - immunology]]></subject><ispartof>International journal of infectious diseases, 2012-05, Vol.16 (5), p.e354-e357</ispartof><rights>International Society for Infectious Diseases</rights><rights>2012 International Society for Infectious Diseases</rights><rights>Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-2d05eb30c22fafdd265d818420d8bd9ddcc92cc3813d47877f65caf9849b96c63</citedby><cites>FETCH-LOGICAL-c455t-2d05eb30c22fafdd265d818420d8bd9ddcc92cc3813d47877f65caf9849b96c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijid.2012.01.005$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,778,782,862,3539,27913,27914,45984</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22387144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yüksel, Nurullah</creatorcontrib><creatorcontrib>Beyazova, Ufuk</creatorcontrib><creatorcontrib>Balci, Işil Fidan</creatorcontrib><creatorcontrib>Aksakal, Fatma Nur</creatorcontrib><creatorcontrib>Çamurdan, Aysu Duyan</creatorcontrib><creatorcontrib>Sahin, Figen</creatorcontrib><creatorcontrib>Rota, Seyyal</creatorcontrib><title>Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey</title><title>International journal of infectious diseases</title><addtitle>Int J Infect Dis</addtitle><description>Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in infants vaccinated with these different schedules. Methods Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and Hib for the first one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series. Results Anti-polyribosylribitol phosphate (anti-PRP) titers ≥0.15 μg/ml were similar in groups 1, 2, and 3. However, in group 1, who received all the vaccines at separate sites, ≥ l.0 μg/ml long-lasting antibody titers and anti-PRP geometric mean titers were higher ( p = 0.001). Conclusion This study showed that even one dose administered in combination with other vaccines in a primary series decreased the level of anti-PRP.</description><subject>Anti-PRP antibodies</subject><subject>Antibodies, Bacterial - blood</subject><subject>Diphtheria Toxoid - administration &amp; dosage</subject><subject>Haemophilus Infections - prevention &amp; control</subject><subject>Haemophilus influenzae type b</subject><subject>Haemophilus influenzae type b - immunology</subject><subject>Haemophilus Vaccines - administration &amp; dosage</subject><subject>Haemophilus Vaccines - immunology</subject><subject>Humans</subject><subject>Immunogenicity</subject><subject>Infant</subject><subject>Infectious Disease</subject><subject>Mass Vaccination</subject><subject>Pertussis Vaccine - administration &amp; dosage</subject><subject>Poliovirus Vaccine, Inactivated - administration &amp; dosage</subject><subject>Polysaccharides - immunology</subject><subject>Population Surveillance</subject><subject>Pulmonary/Respiratory</subject><subject>Tetanus Toxoid - administration &amp; dosage</subject><subject>Turkey</subject><subject>Vaccination schedule</subject><subject>Vaccines, Acellular - administration &amp; dosage</subject><subject>Vaccines, Combined - administration &amp; dosage</subject><subject>Vaccines, Combined - immunology</subject><issn>1201-9712</issn><issn>1878-3511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UktuFDEQbSEQCYELsEBespnBdv_cEkJCUSCRIrEgrC23XZ1x020P_kw0WXEHjsUtOAnVzIQFC1Zl6X1cVa-K4iWja0ZZ82Zc29GaNaeMrylbU1o_Kk6ZaMWqrBl7jG-EVl3L-EnxLMaRUlo1jXhanHBeipZV1Wnx82qes_O34Ky2aU_8QBS5VDD77cZOORLrhimDu1dA0n4LpP_1_UeCpBxi2rsx36oEZKe0tg7I3QYcUWa2zsYEAQyJsFUBKRN6B3RD0dwj1TxoIhkQ2AY7q7AndmnH3qtkvVvY6c4v30TQOdkdEPcHUROJegMmT7B0SG5y-Ar758WTQU0RXhzrWfHlw8XN-eXq-tPHq_P31ytd1XVacUNr6EuqOR_UYAxvaiOYqDg1ojedMVp3XOtSsNJUrWjboam1GjpRdX3X6KY8K14ffLfBf8sQk5xt1DBNyoHPUTJKWVeXbSOQyg9UHXyMAQZ5HBRJcglRjnIJUS4hSsokhoiiV0f_3M9g_koeUkPC2wMBcMqdhSCjtuA0GBtAJ2m8_b__u3_kesLAtJpwiRBHnwNuGOeQETXy83JGyxVhpbQUtPwNcwLKbg</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Yüksel, Nurullah</creator><creator>Beyazova, Ufuk</creator><creator>Balci, Işil Fidan</creator><creator>Aksakal, Fatma Nur</creator><creator>Çamurdan, Aysu Duyan</creator><creator>Sahin, Figen</creator><creator>Rota, Seyyal</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey</title><author>Yüksel, Nurullah ; Beyazova, Ufuk ; Balci, Işil Fidan ; Aksakal, Fatma Nur ; Çamurdan, Aysu Duyan ; Sahin, Figen ; Rota, Seyyal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-2d05eb30c22fafdd265d818420d8bd9ddcc92cc3813d47877f65caf9849b96c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-PRP antibodies</topic><topic>Antibodies, Bacterial - blood</topic><topic>Diphtheria Toxoid - administration &amp; dosage</topic><topic>Haemophilus Infections - prevention &amp; control</topic><topic>Haemophilus influenzae type b</topic><topic>Haemophilus influenzae type b - immunology</topic><topic>Haemophilus Vaccines - administration &amp; dosage</topic><topic>Haemophilus Vaccines - immunology</topic><topic>Humans</topic><topic>Immunogenicity</topic><topic>Infant</topic><topic>Infectious Disease</topic><topic>Mass Vaccination</topic><topic>Pertussis Vaccine - administration &amp; dosage</topic><topic>Poliovirus Vaccine, Inactivated - administration &amp; dosage</topic><topic>Polysaccharides - immunology</topic><topic>Population Surveillance</topic><topic>Pulmonary/Respiratory</topic><topic>Tetanus Toxoid - administration &amp; dosage</topic><topic>Turkey</topic><topic>Vaccination schedule</topic><topic>Vaccines, Acellular - administration &amp; dosage</topic><topic>Vaccines, Combined - administration &amp; dosage</topic><topic>Vaccines, Combined - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yüksel, Nurullah</creatorcontrib><creatorcontrib>Beyazova, Ufuk</creatorcontrib><creatorcontrib>Balci, Işil Fidan</creatorcontrib><creatorcontrib>Aksakal, Fatma Nur</creatorcontrib><creatorcontrib>Çamurdan, Aysu Duyan</creatorcontrib><creatorcontrib>Sahin, Figen</creatorcontrib><creatorcontrib>Rota, Seyyal</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yüksel, Nurullah</au><au>Beyazova, Ufuk</au><au>Balci, Işil Fidan</au><au>Aksakal, Fatma Nur</au><au>Çamurdan, Aysu Duyan</au><au>Sahin, Figen</au><au>Rota, Seyyal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey</atitle><jtitle>International journal of infectious diseases</jtitle><addtitle>Int J Infect Dis</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>16</volume><issue>5</issue><spage>e354</spage><epage>e357</epage><pages>e354-e357</pages><issn>1201-9712</issn><eissn>1878-3511</eissn><abstract>Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in infants vaccinated with these different schedules. Methods Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and Hib for the first one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series. Results Anti-polyribosylribitol phosphate (anti-PRP) titers ≥0.15 μg/ml were similar in groups 1, 2, and 3. However, in group 1, who received all the vaccines at separate sites, ≥ l.0 μg/ml long-lasting antibody titers and anti-PRP geometric mean titers were higher ( p = 0.001). Conclusion This study showed that even one dose administered in combination with other vaccines in a primary series decreased the level of anti-PRP.</abstract><cop>Canada</cop><pub>Elsevier Ltd</pub><pmid>22387144</pmid><doi>10.1016/j.ijid.2012.01.005</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1201-9712
ispartof International journal of infectious diseases, 2012-05, Vol.16 (5), p.e354-e357
issn 1201-9712
1878-3511
language eng
recordid cdi_proquest_miscellaneous_1001953768
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ScienceDirect Journals (5 years ago - present)
subjects Anti-PRP antibodies
Antibodies, Bacterial - blood
Diphtheria Toxoid - administration & dosage
Haemophilus Infections - prevention & control
Haemophilus influenzae type b
Haemophilus influenzae type b - immunology
Haemophilus Vaccines - administration & dosage
Haemophilus Vaccines - immunology
Humans
Immunogenicity
Infant
Infectious Disease
Mass Vaccination
Pertussis Vaccine - administration & dosage
Poliovirus Vaccine, Inactivated - administration & dosage
Polysaccharides - immunology
Population Surveillance
Pulmonary/Respiratory
Tetanus Toxoid - administration & dosage
Turkey
Vaccination schedule
Vaccines, Acellular - administration & dosage
Vaccines, Combined - administration & dosage
Vaccines, Combined - immunology
title Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A57%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20a%20Haemophilus%20influenzae%20type%20b%E2%80%93tetanus%20conjugate%20vaccine%20when%20administered%20separately%20or%20in%20combined%20vaccines%20for%20primary%20immunization%20in%20two%20consecutive%20national%20schedules%20in%20Turkey&rft.jtitle=International%20journal%20of%20infectious%20diseases&rft.au=Y%C3%BCksel,%20Nurullah&rft.date=2012-05-01&rft.volume=16&rft.issue=5&rft.spage=e354&rft.epage=e357&rft.pages=e354-e357&rft.issn=1201-9712&rft.eissn=1878-3511&rft_id=info:doi/10.1016/j.ijid.2012.01.005&rft_dat=%3Cproquest_cross%3E1001953768%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1001953768&rft_id=info:pmid/22387144&rft_els_id=S1201971212000380&rfr_iscdi=true